Actavis Group, the international generic pharmaceuticals company, has announced the launch of Rabeprazole in Germany, France, Spain, the Netherlands and UK immediately after the patents expired on 12-13 November. The product will be launched in Italy shortly. In Austria, Actavis started the pricing process on day one.
Developed and manufactured by Actavis in Iceland, Rabeprazole Sodium Actavis is the generic equivalent of Janssen Pharmaceuticals’ brand product Pariet®.
According to IMS Health, branded Rabeprazole sales in Europe were €305 million for the year ending June 2012.
Rabeprazole is a proton pump inhibitor that inhibits the production of gastric acid in the stomach and is therefore used in the treatment of various conditions related to problems with gastric acid.